Reference
- Rizvi, N. A. et al. Mutational landscape determines sensitivity to
PD-1 blockade in non-small cell lung cancer. Science 348,
124–128 (2015).
- Hugo, W. et al. Genomic and transcriptomic features of response to
anti-PD-1 therapy in metastatic melanoma. Cell 165, 35–44
(2016).
- Rosenberg, J. E. et al. Atezolizumab in patients with locally advanced
and metastatic urothelial carcinoma who have progressed following
treatment with platinum-based chemotherapy: a single-arm, multicentre,
phase 2 trial. Lancet 387, 1909–1920 (2016).
- Velcheti V, Kim ES, et al. Prospective clinical evaluation of
blood-based tumor mutational burden (bTMB) as a predictive biomarker
for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC):
interim B-F1RST results. J Clin Oncol 2018;36(15_suppl):
12001–01.
- Hellmann MD, Ciuleanu TE, et al. Nivolumab plus Ipilimumab in lung
Cancer with a high tumor mutational burden. N Engl J Med .
2018;378(22):2093–104.
- Gao, J. et al. Integrative analysis of complex cancer genomics and
clinical profiles using the cBioPortal. Sci Signal. 2013 Apr
2;6(269)
- Robert M. Samstein. Et al. Tumor mutational load predicts survival
after immunotherapy across multiple cancer types. Nat Genet.2019 Feb;51(2):202-206.
- Hugo, W. et al. Genomic and transcriptomic features of response to
anti-PD-1
therapy in metastatic melanoma. Cell. 2016 Mar 24;165(1):35-44.
- Hellmann M D, Ciuleanu T, Pluzanski A, et al. Nivolumab plus
Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.The New England Journal of Medicine , 2018, 378(22): 2093-2104.
- Snyder A, Makarov V, et al. Genetic basis for clinical response to
CTLA-4 blockade in melanoma. N Engl J Med 2014;371: 2189-99.
- Carbone DP, Reck M, et al. First-Line Nivolumab in Stage IV or
Recurrent Non-Small-Cell Lung Cancer. N Engl J Med 2017;376:
2415-26.
- Hellmann MD, Callahan MK, et al. Tumor Mutational Burden and Efficacy
of Nivolumab Monotherapy and in Combination with Ipilimumab in
Small-Cell Lung Cancer. Cancer Cell 2018;33: 853-61 e4.
- Rosenberg JE, Hoffman-Censits J, et al. Atezolizumab in patients with
locally advanced and metastatic urothelial carcinoma who have
progressed following treatment with platinum-based chemotherapy: a
single-arm, multicentre, phase 2 trial. Lancet 2016;387:
1909-20.
- Bojovic, B. & Crowe, D. L. Dysfunctional telomeres promote genomic
instability and metastasis in the absence of telomerase activity in
oncogene induced mammary cancer. Mol. Carcinogen. 2013
Feb;52(2):103-17.
- Vermaat, J. S. et al. Primary colorectal cancers and their
subsequent hepatic metastases are genetically different: implications
for selection of patients for targeted treatment. Clin. Cancer
Res. 2012 Feb 1;18(3):688-99.
- Yachida, S. et al. Distant metastasis occurs late during the
genetic evolution of pancreatic cancer. Nature. 2010 Oct
28;467(7319):1114-7.
- Roschke, A. et al. Chromosomal instability is associated with
higher expression of genes implicated in epithelial-mesenchymal
transition, cancer invasiveness, and metastasis and with lower
expression of genes involved in cell cycle checkpoints, DNA repair,
and chromatin
maintenance. Neoplasia. 2008 Nov;10(11):1222-30.
- Hong, M. K. H. et al. Tracking the origins and drivers of
subclonal metastatic expansion in prostate cancer. Nat. Commun.2015 Apr 1;6:6605.
- Brastianos, P. et al. Genomic characterization of brain
metastases reveals branched evolution and potential therapeutic
targets. Cancer Discov. 2015 Nov;5(11):1164-1177.
- Rooney, M. S., Shukla, S. A., et al. Molecular and genetic properties
of tumors associated with local immune cytolytic activity.Cell. 2015 Jan 15;160(1-2):48-61.
- Balachandran, V. P. et al. Identifcation of unique neoantigen
qualities in long-term survivors of pancreatic cancer. 2017 Nov
23;551(7681):512-516.
- Topalian, S. L. et al. Safety, activity, and immune correlates of
anti-PD-1 antibody in cancer. N. Engl. J. Med. 2012 Jun
28;366(26):2443-54.
- McGranahan, N. et al. Clonal neoantigens elicit T cell
immunoreactivity and sensitivity to immune checkpoint blockade.Science, 2016 Mar 25;351(6280):1463-9.